- Delic Labs just received its Health Canada 56 Research Exemption, enabling it to develop innovative analytical methods for psychedelic research
- The company first applied for the exemption in October 2021, along with a Dealer’s License for commercializing psilocybin research and associated IP for medical and research purposes
- With this significant milestone, Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced by them
- Delic’s management believes that the company is on the cusp of understanding the breadth of what is possible with psychedelics and medicine
Back in October 2021, Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, applied for a Health Canada 56 Research Exemption that would allow scientists to conduct research and tests on various compounds outside of psychedelic mushrooms, including MDMA and LSD (https://ibn.fm/XhQGc).
The company finally received its exemption on April 13, allowing it to perform tests and acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. (https://ibn.fm/Rp2R4).
“Securing our latest Health Canada 56 exemptions allow us to advance our research efforts as we continue to understand the medical applications of psychedelic compounds,” noted Dr. Markus Roggen, the co-founder of Delic labs.
“Psychedelics show tremendous promise as a new class of therapeutics, and Delic Labs is taking extensive measures to establish best practices in developing and manufacturing these potential treatments,” he added.
In addition to the Health Canada 56 Research Exemption application, Delic Labs also applied for a Dealer’s License for commercializing psilocybin research and associated intellectual property (“IP”) for medical and research purposes. While it is yet to be granted, Delic is confident that securing this license, coupled with the existing research exemptions, will cement Delic Labs’ position as a leader in psychedelic safety testing.
Matt Stang, Delic Corp’s co-founder, terms the exemption as a giant leap forward for the company and an affirmation of its position as a leader in its space.
“Never before has a lab been authorized to test psychedelic compounds such as MDMA and LAD with the opportunity to create new medicines for millions suffering from debilitating conditions like depression, anxiety, PTSD, and Parkinson’s disease,” he noted.
“Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced using them, while also actively researching potential new medicines for the market,” he added.
Delic’s management believes that the company is on the cusp of understanding the breadth of what is possible with psychedelics and medicine. The exceptions are a giant leap forward for the company. It is only a matter of time before it starts introducing new psychedelic drugs and grows its IP for the benefit of individuals living with mental health conditions.
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment